Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Affiliations

• ¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, Germany.
• ² Praxis für Hämatologie und Onkologie Cottbus, Cottbus, Germany.
• ³ BAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Landshut, Germany.
• ⁴ Onkologie Ravensburg, Ravensburg, Germany.
• ⁵ Onkologie und Palliativmedizin Hamburg, Praxis für Hämatologie, Hamburg, Germany.
• ⁶ Klinikum Lippe Standort Lemgo, Lemgo, Germany.
• ⁷ Medizinische Klinik III, University Hospital of Rostock, Rostock, Germany.
• ⁸ Innere Medizin III, University Hospital Schleswig Holstein, Kiel, Germany.
• ⁹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
• ¹⁰ Division of CLL, Klinik für Innere Medizin III, University Hospital Ulm, Ulm, Germany.
• ¹¹ Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University (LMU), Munich, Germany.